Amendments to the Claims:

This listing of claims will replace all prior versions and listing of claims in the application. OK TO ENTER: PLM/(12/07/2009)

Listing of Claims:

Claim 1 (previously presented): A compound of formula (I) or a salt thereof,

$$R^{1}$$
 R^{2}
 R^{3}
 R^{3}
 R^{3}

wherein:

Ring A is pyridin-2-yl wherein said pyridin-2-yl is optionally substituted on carbon by one or more groups selected from R⁴;

one of \mathbb{R}^1 and \mathbb{R}^2 is hydrogen and the other is hydrogen or C_{1-4} alkyl; wherein \mathbb{R}^1 and \mathbb{R}^2 are optionally substituted on carbon by one or more groups selected from \mathbb{R}^5 ;

 R^3 is selected from C_{1-4} alkyl, C_{1-4} alkoxy, carbocyclyl, and carbocyclyloxy; wherein R^3 is optionally substituted on carbon by one or more groups selected from R^6 ;

 ${\bf R}^4$ is selected from halo, carboxy and $C_{1\text{-}4}$ alkyl;

 ${f R}^5$ and ${f R}^6$ are independently selected from halo, C_{1-4} alkyl, C_{1-4} alkoxy, N-(C_{1-4} alkyl)amino, N, N-(C_{1-4} alkyl)₂amino, carbocyclyl, carbocyclyloxy, and carbocyclylidenyl; wherein ${f R}^5$ and ${f R}^6$ are independently optionally substituted on carbon by one or more ${f R}^7$;

R⁷ is selected from halo, carboxy, methyl, ethyl, methoxy, ethoxy, methylamino, ethylamino, dimethylamino, diethylamino and *N*-methyl-*N*-ethylamino.

Claim 2 (previously presented): The compound according to Claim 1 or a salt thereof, wherein Ring A is unsubstituted or is substituted by carboxy.

Claim 3 (previously presented): The compound according to Claim 2 or a salt thereof, wherein one of \mathbb{R}^1 and \mathbb{R}^2 is hydrogen and the other is hydrogen or C_{1-4} alkyl.

Claim 4 (previously presented): The compound according Claim 1 or a salt thereof, wherein \mathbf{R}^3 is selected from $C_{1\rightarrow 4}$ alkoxy; wherein \mathbf{R}^3 is optionally substituted on carbon by one or more groups selected from \mathbf{R}^6 .

Claim 5 (currently amended): The compound according to Claim 1 or a salt thereof, wherein **R**³ is selected from-2-fluorobenzyloxy, 5-methylisoxazol-3-ylmethoxy and 2-thien-3-ylethoxy.

Claim 6 (currently amended): A compound according to Claim 1 selected from:

2-methyl-4-isobutoxy-6-[N-(5-carboxypyridin-2-yl)carbamoyl]benzofuran;

2-methyl-4-(2-fluorophenylmethoxy)-6-[N-(5-carboxypyridin-2-yl)carbamoyl]benzofuran;

2-methyl-4-isobutoxy-6-[N-(5-carboxythiazol-2-yl)carbamoyl]benzofuran;

2-methyl-4-(5-methylisoxazol-3-ylmethoxy)-6-[N-(5-carboxypyridin-2-yl)carbamoyl]benzofuran;

4-(2-fluorophenylmethoxy)-6-[N-(5-carboxypyridin-2-yl)carbamoyl]benzofuran;

4-(5-methyl-4-isobutoxy-6-[N-(5-carboxypyridin-2-yl)carbamoyl]benzofuran;

2-methyl-4-(thien-2-ylethoxy)-6-[N-(5-carboxypyridin-2-yl)carbamoyl]benzofuran; and

2-methyl-4-isobutoxy-6-[N-(thiazol-2-yl)carbamoyl]benzofuran;

Claim 7 (previously presented): A pharmaceutical composition comprising a compound according to any one of Claims 1 to 6, or a salt thereof, together with a pharmaceutically acceptable diluent or carrier.

or a salt thereof.

Claim 8 (previously presented): A method of treating type 2 diabetes, comprising administering an effective amount of a compound according to any one of Claims 1 to 6 or a salt thereof.

Claims 9-12 (canceled)